Comparison between abluminal biodegradable polymer ultrathin sirolimus-eluting stent and durable-polymer everolimus-eluting stent (GENOSS randomized clinical trial)
Not Applicable
- Conditions
- Diseases of the circulatory system
- Registration Number
- KCT0007397
- Lead Sponsor
- Samsung Medical Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot yet recruiting
- Sex
- All
- Target Recruitment
- 850
Inclusion Criteria
? 19 years of age or older
? Patients diagnosed with stable coronary artery disease or acute coronary syndrome and with more than 50% coronary stenosis requiring stent insertion
? A person who can voluntarily sign the consent form
Exclusion Criteria
? If the following drugs are irritable or contraindicated (aspirin, clopidogrel, ticagrelor, prasugrel, heparin, sirolimus, or everolimus)
? a pregnant woman
? A person who is expected to have a life expectancy of less than one year due to non-heart disease or less compliant with treatment (as determined by medical judgment by the investigator)
? Patients who refused to participate in the study
Study & Design
- Study Type
- Interventional Study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Cardiac death, target vascular myocardial infarction, and target lesion revascular surgery are synthesized as target lesion failure (TLF).
- Secondary Outcome Measures
Name Time Method Target lesion failure